We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
Daily historical data with per-account defaults
Filings, earnings, research, and institutional changes — newest first
표시할 이벤트가 없습니다.
Consensus vs. actual, and revenue trend
| 분기 | 발표일 | 시각 | EPS 예상 | EPS 실제 | 서프라이즈 | 매출 예상 | 매출 실제 | 상태 |
|---|---|---|---|---|---|---|---|---|
| — | 2026. 07. 29. | 장 마감 후 (AMC) | — | — | — | $661.4K | — | 예정 |
| FY2026 Q1 | 2025. 03. 31. | 시각 미정 | — | $-0.26 | — | — | $800K | 보고됨 |
| FY2025 Q3 | 2024. 09. 30. | 시각 미정 | — | $-0.95 | — | — | $3.64M |
Rating & price-target changes
표시할 리서치 액션이 없습니다.
동일 리서치펌의 과거 의견 변화, 동일 섹터 내 다른 종목 액션과 비교 가능
| FY2025 Q2 | 2024. 06. 30. | 시각 미정 | — | $-0.63 | — | — | $2.57M | 보고됨 |
공시·실적·기관 변화를 한국어 한 단락으로 요약. 원문 출처와 함께 제공됩니다.
Ranked by position value
표시할 보유 데이터가 없습니다.
신규 편입·전량 매도·비중 변화까지 모두 확인할 수 있습니다.
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs include celiac disease. In addition, the company develops Viaskin technology platform, a platform to potentially treat food allergy. It has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Châtillon, France.
Stored first · Google News · Yahoo Finance (English)